Abstract 1682P
Background
Prostate cancer (PC) presents a significant health challenge in Africa, especially in regions like Nigeria with limited access to care. Despite medical advancements, PC treatment affects patients beyond their physical health, impacting their quality of life (QoL) and financial toxicity (FT) due to high treatment costs and inadequate insurance coverage. Patient-reported outcomes are often overlooked in African PC research, creating knowledge gaps that need to be addressed.
Methods
This descriptive cross-sectional study aimed to assess patient-reported outcomes among male PC patients at Lagos University Teaching Hospital (LUTH) and the NSIA-LUTH Cancer Centre (NLCC). Data collection involved interviewer-based structured questionnaires that inculcated QoL (FACT-P), psychosocial distress (PHQ-4), and FT (FACIT-COST). Analysis was done with RStudio, with a P-value set at <0.05 for statistical significance. Ethical approval was obtained.
Results
This study examined 200 prostate cancer patients at LUTH. Participants were primarily aged 61–70; most are married with tertiary education, and the majority are retired. Comorbidities, particularly hypertension (32.0%) and diabetes mellitus (22.5%), are prevalent. Notable findings include the impact of age, employment status, and comorbidities on QoL and FT. ECOG scores, cancer stage, and comorbidities significantly influence psychological distress levels. Associations between QoL, financial toxicity, and psychosocial distress underscore the complex interplay between these factors. No significant link was found between QoL and FT.
Conclusions
This study sheds light on the challenges faced by PC patients at LUTH, highlighting the complex interplay of factors. Economic challenges included limited health insurance coverage and financial strain. Early detection and intervention are crucial, given the distribution of cancer stages and the prevalence of comorbidities among patients. FT emerges as a significant issue, impacting patients' QoL and psychosocial well-being. The lack of significant associations with health insurance coverage suggests the need for comprehensive healthcare reforms.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
R. O. Jimoh.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1687P - Perceptions of genetic testing and lived experiences in women with locally advanced or metastatic ovarian cancer: A focus on BRCAm and BRCAwt patients
Presenter: María Jesús Rubio Pérez
Session: Poster session 11
1688P - Psychosocial distress and spirituality among elderly patients with cancer in Nigeria
Presenter: Zainab Ogunjimi
Session: Poster session 11
1689TiP - The social stigma of smokers and patients with lung cancer: Detection of phoenomenon and testing of EMDR (eye movement desensitization and reprocessing) intervention
Presenter: Domenico Galetta
Session: Poster session 11
1692P - A phase Ib/IIa trial to evaluate the safety and efficacy of PM8002/ BNT327, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced renal cell carcinoma
Presenter: Xinan Sheng
Session: Poster session 11
1693P - CaboPoint: Final results from a phase II study of cabozantinib after checkpoint inhibitor (CPI) combinations in patients with advanced renal cell carcinoma (aRCC)
Presenter: Laurence Albiges
Session: Poster session 11
1695P - Phase I LITESPARK-018: Dose escalation study of belzutifan in advanced pretreated clear cell renal cell carcinoma (ccRCC)
Presenter: Ulka Vaishampayan
Session: Poster session 11
1696P - A phase I/ II trial of pazopanib (Paz) alternating (alt) with bevacizumab (Bev) in treatment-naïve metastatic clear cell renal cell carcinoma (mccRCC) patients (pts): Phase II results
Presenter: Saby George
Session: Poster session 11
1697P - Phase II randomized double-blind trial of axitinib (Axi) +/- PF 04518600, an OX40 antibody (PFOX) after PD1/PDL1 antibody (IO) therapy (Tx) in metastatic renal cell carcinoma (mRCC): Final analysis
Presenter: Sarmad Sadeghi
Session: Poster session 11
1698P - Avelumab + axitinib (Ave + Axi) vs sunitinib (Sun) in advanced renal cell carcinoma (aRCC): Final analysis of patient (pt)-reported outcomes (PROs) and quality-adjusted time without symptoms or toxicity (Q-TWiST)
Presenter: Balaji Venugopal
Session: Poster session 11